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Abstract
Background RNA editing is catalyzed by adenosine deami-
nases acting on RNA (ADARs). ADAR2 is the main enzyme
responsible for recoding editing in humans. Adenosine-to-
inosine (A-to-I) editing at the Q/R site is reported to be
decreased in gliomas; however, the expression of ADAR2
mRNAwas not greatly affected.
Methods We determined ADAR2 mRNA expression in hu-
man glioblastoma cell lines and in normal human glial cells by
real-time RT-PCR. We also determined ADAR2 mRNA ex-
pression in 44 glioma tissues and normal white matter. After
identifying an alternative splicing variant (ASV) of ADAR2
in gliomas, we performed sequencing. We then classified
glioblastomas based on the presence (+) or absence (–) of
the ASV to determine the correlations between ASV+and
malignant features of glioblastomas, such as invasion,
peritumoral brain edema, and survival time.
Results There were no significant differences in ADAR2
mRNA expression among human glioblastoma cell lines or in
gliomas compared with normal white matter (all p>0.05). The
ASV, which contained a 47-nucleotide insertion in the ADAR2
mRNA transcript, was detected in the U251 and BT325 cell
lines, and in some glioma tissues. The expression rate of ASV
differed among gliomas of different grades. ASV+glioblasto-
mas were more malignant than ASV – glioblastomas.
Conclusions ADAR2 is a family of enzymes in which ASVs
result in differences in enzymatic activity. The ADAR2 ASV
may be correlated with the invasiveness of gliomas. Identifi-
cation of the mechanistic characterization of ADAR2 ASV
may have future potential for individualized molecular
targeted-therapy for glioma.
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Introduction
Gliomas are the most common primary malignant brain tumor
in humans. They can be typed as low-grade astrocytomas
(LGA), oligodendrogliomas (OG), anaplastic astrocytomas
(AA), and glioblastomas multiforme (GBM), among other
subtypes. These tumors are often invasive, making surgical
resection difficult. Despite the best treatment regimen current-
ly available, which consists of surgery, radiotherapy, and
systematic chemotherapy, the prognosis of patients with glio-
mas is poor. The 5-year survival of patients with GBM is less
than 3 % [4, 32].
The widespread RNA–DNA variations found in human
brain tissues indicate that RNA sequences are not identical
to their corresponding DNA sequences [19]. Most RNA–
DNA differences are caused by RNA editing, a process that
generates many different mRNAs from the same gene after the
post-transcriptional events [2, 3, 8, 23]. The potential impact
of RNA editing on the etiology or progression of human
diseases has now been realized. Deficient or hyperactive
adenosine-to-inosine (A-to-I) RNA editing is associated with
several human diseases including epilepsy, malignant brain
cancer, amyotrophic lateral sclerosis, immunological disor-
ders, and depression [13, 21, 31]. The analysis of RNA editing
in various cancers, including brain, prostate, lung, kidney,
bladder, colorectal, and testicular tumors, is expected to pro-
vide new diagnostic and prognostic markers [6, 7, 11, 12, 26,
28].
In mammals, RNA editing by site-selective adenosine de-
amination regulates the key functional properties of neuro-
transmitter receptors in the central nervous system [2]. Many
RNA editing sites have now been reported [3, 8, 9, 21].
Almost all editing of the glutamate receptor (GluR) subunit
B (GluR-B) occurs at one position, the Q/R-site, in a process
that is essential for normal receptor function [4, 16, 34]. A
general decrease in RNA editing activity has been observed in
malignant gliomas in the brain. The Q/R site of GluR-B is
frequently underedited in malignant gliomas compared with
control tissues [5, 22, 32]. Alu sequences within MED13
transcripts are also underedited in brain tumors [26]. RNA
editing is performed by adenosine deaminases acting on RNA
(ADARs), of which ADAR2 is the main enzyme responsible
for recoding editing in the brain [24, 31]. However, the
ADAR2mRNA expression levels in gliomas were inconsistent
in three previous reports. Furthermore, there was no consistent
correlation between editing efficiency and ADAR2 mRNA
expression level in those studies [5, 22, 26, 32]. Therefore,
the regulation of the RNA editing activity of ADAR2 in vivo is
still largely unknown.
In this study, we determined ADAR2 mRNA expression
levels in glioma-derived cell lines and in glioma tissues. We
have presented evidence for an alternative splicing variant
(ASV) of ADAR2 in gliomas. Furthermore, we explored the
correlation between ADAR2 ASV expression and the inva-
siveness of GBM. We demonstrate that (1) ADAR2 mRNA
levels were not altered in glioma-derived cell lines or in
glioma tissues; (2) self-editing of ADAR2 pre-mRNA gener-
ates an ADAR2 ASV in glioma-derived cell lines and glioma
tissues; and (3) the ADAR2 ASV may be correlated with the
invasiveness of gliomas.
Materials and methods
Clinical specimens and cell lines
Glioma tissues and normal white matter tissue samples were
obtained from the China–Japan Union Hospital and the First
Hospital of Jilin University, Changchun, China between Jan-
uary 2007 and June 2008. Tumor tissue samples were taken
from 44 patients with a primary glioma (age range at the time
of diagnosis, 17–55 years). None of the patients previously
received radiotherapy or chemotherapy. Tumor tissue samples
were dissected from both the core and the edge of the tumors.
Diagnosis was defined according to the guidelines of the
World Health Organization, and was obtained by two glioma
neuropathologists who performed independent immunohisto-
chemical analyses of all of glioma samples. Tumor tissues
included 12 cases of GBM, eight cases of AA, 10 cases of
LGA, and six cases of OG. As normal controls, we used six
non-tumoral white matter samples obtained from six
anonymized patients (age range at the time of diagnosis, 21–
54 years) undergoing focal brain resection during acute inter-
nal decompression operation for severe traumatic brain injury
such as brain contusions [5, 32]. As normal controls, we
choose white matter because tumor cells of gliomas originate
from glial cells which are particularly abundant in white
matter [17]. We obtained IRB approval prior to obtaining the
normal white matter samples from the six patients [15]. Tumor
and control tissues were frozen immediately after their remov-
al at surgery and were kept at −70 °C until further use. The
number of samples tested in each assay differed because of the
limited amount of RNA that was available for each sample.
The study obtained IRB approval regarding the use of human
samples for experimental studies from the ethics committees
of China–Japan Union Hospital and the First Hospital of Jilin
University, China.
An astrocytoma cell line (SHG44) and two human GBM
cell lines (U251 and BT325) were obtained from the Cell
Center of the Chinese Academic Medical College (Beijing,
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China). Glioma cells were routinely cultured in Dulbecco’s
modified Eagle’s medium (GIBCO®; Life Technologies, Inc.,
Gaithersburg, MD, USA) at 37 °C under 5 % CO2. Normal
human astrocytes (NHA) (#CC-2565, Lot 80982; Lonza,
Walkersville, MD, USA) were grown in a humidified incuba-
tor at 37 °C under 5 % CO2.
RNA extraction and real-time RT-PCR
Total RNA was extracted from the clinical samples and
cultured cells using Trizol (Invitrogen, Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. Quantitative real-time PCR of ADAR2 cDNA
was performed using an Mx3000P real-time PCR instru-
ment (Agilent, Santa Clara, CA, USA) with SYBR green I
fluorescence, as follows. The reaction mixture consisted of
12.5 μL of 2× SYBR, 0.5 μL each of the forward (5′-
GTATTTTGCCATGGA TATAGAAGATG-3′; sense, exon
1, 10 μmol L−1) and reverse primers (5′-GTACTGGGAT
CCAGGCTTGATCTCATTCAGCTG-3′; antisense, exon 2,
10 μmol L−1), and 2.0 μL of cDNA 2.0 μL, in a final
reaction volume of 25 μL with DNase- and RNase-free
water. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; assay ID Hs9999905_m1; Applied Biosystems,
Foster City, CA, USA) was used as a reference gene. The
PCR conditions consisted of 10 min at 95 °C, followed
by 45 cycles of 95 °C for 20 s, 60 °C for 30 s, and
72 °C for 45 s. Real-time PCR was performed using serial
dilutions of each cDNA template (1×, 1:4, 1:16, 1:64, and
1:256). The cycle threshold (Ct value) was defined as the
number of cycles required to reach the fluorescence
threshold. As a representative example, an amplification
plot was generated for ADAR2 in which fluorescence
intensity was plotted against cycle number. The compara-
tive Ct method was used to quantify transcript number,
and the normalized Ct value (2–ΔΔCt) was used to esti-
mate the level of ADAR2 gene expression. The odds ratio
and 95 % confidence interval were calculated automatical-
ly by UNPHASED software (MRC Biostatistics Unit,
Cambridge, UK). Real-time assays were performed in
triplicate from two independent RT reactions.
RT-PCR
cDNA was synthesized using SuperScript II reverse
transcriptase (Invitrogen) and random hexamer primers.
To analyze human ADAR2 alternative splicing, we per-
formed PCR reactions using forward (5′-GTATTTTGCC
ATGGATATAGAAGATG-3′; sense, exon 1) and reverse
primers (5′-GTACTGGGATCCAGGCTTGATCTCATTC
AGCTG-3′; antisense, exon 2), which amplified both
splice variants from cDNA.
Calculation of peritumoral brain edema (PTBE)
PTBE contributes to the morbidity and mortality of brain
tumors. The development of PTBE is influenced by many
factors. PTBE in brain tumors might be a prognostic indicator
of patient survival [25]. The extent of PTBE and tumor size
were measured by magnetic resonance imaging (MRI) [25].
The tumor volume was measured on enhanced T1 weighted
images and the volume of edema surrounding the tumors was
measured on T2 weighted images [33]. The edema/tumor
volume ratio was defined as the edema index (EI), and was
used as an indicator of PTBE [30]. EI was calculated as PTBE
area/tumor area. Thus, if EI=1, there is no PTBE [14]. An EI
of ≤3 was defined as weak PTBE (+), an EI of >3 to <7 was
defined as moderate PTBE (++), and an EI of ≥7 was defined
as strong PTBE (+++) [33].
Statistical analysis
SPSS for Windows (version 14.0; SPSS, Inc., Chicago, IL,
USA) was used to perform the Mann–Whitney U test to
examine the difference in ADAR2 expression between pa-
tients and controls. Survival rates were estimated by the
Kaplan–Meier method and overall survival was compared
between patients with (+) and without (–) an ADAR2 ASV
using the log-rank test. Statistical significance (p<0.05) was
determined by descriptive statistics.
Results
ADAR2 expression in human glioblastoma cell lines
Quantitative real-time RT-PCR revealed no marked differ-
ences in ADAR2 mRNA expression between NHA, SHG44,
U251, and BT325 cells (Fig. 1).
ADAR2 mRNA expression in human gliomas
We performed semi-quantitative RT-PCR using 44 glioma
samples, and performed quantitative real-time RT-PCR using
six normal white matter tissue samples and 36 glioma samples
(12 GBM, eight AA, 10 LGA, and six OG). We found that
ADAR2 mRNA expression was not significantly different
between the gliomas and normal white matter tissues (all
p>0.05; Fig. 2a).
Expression of ADAR2 ASVs in glioma cell lines
RT-PCR amplification of total RNA isolated from the NHA
and SHG44 cells presented a single electrophoretic band. RT-
PCR amplification of total RNA isolated from the glioma-
derived cell line U251 and BT325 revealed two distinct
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electrophoretic bands (Fig. 2b). Sequence analysis of both
isolated ADAR2 cDNAs indicated that these two isoforms
were produced by alternative splicing. The longer isoforms
contained a 47-nucleotide sequence (GATCCTGCAACGAA
GGCGTTGTAAGTTACTCTTTCTGGGCACCACAG)
inserted after the first 28 nucleotides of the coding region. This
ASV is identical to the one that was previously identified in a
human ADAR2 transcript containing a 47-nucleotide insertion
at the analogous position [18, 20, 27].
Expression of ADAR2 ASVs in glioma tissues
In glioma samples, we detected ADAR2 ASV mRNA which
was identical to that found in the U251 and BT325 cell lines.
The ASV was not detected in any of the normal human brain
tissue samples. The ADAR2 ASV was expressed in 1/10
LGAs, 1/6 OGs, 1/8 AAs, and 3/12 GBMs, corresponding
to rates of self-editing induced ASVs of 10%, 16.7%, 12.5%,
and 25 %, respectively. The expression of the ASV was
highest in GBMs, the most aggressive type of gliomas. The
level of ASV expression was correlated with tumor grade
(Fig. 2c).
ADAR2 ASVexpression is correlated with the extent
of PTBE in patients with GBM
Patients with GBM were classified into two groups according
to the presence (+; n=3) or absence (–; n=9) of the ADAR2
ASV. For the three ADAR2 ASV+patients, weak, moderate,
and strong EI scores were observed in 0 (0 %), 0 (0 %), and
three (100 %) patients, respectively. By contrast, the EI scores
were classified as weak, moderate, and strong in seven (78%),
two (22 %), and 0 (0 %) in the ADAR2 ASV – patients,
respectively (Table 1). The EI scores were significantly greater
in the ADAR2 ASV+patients than in the ADAR2 ASV –
patients (p<0.01).
ADAR2 ASVexpression and the invasiveness of GBM
To analyze the association between ADAR2 ASV expression
and invasiveness of GBM,we usedMRI to examine the extent
of tumor invasion in the GBM patients. For the three ADAR2
ASV+patients, the tumor had invaded two lobes in one pa-
tient and three lobes in two patients. By contrast, among the
Fig. 1 Relative ADAR2 expression levels in human glioma cell lines.
Real-time RT-PCR for ADAR2 was performed using a human astrocyto-
ma cell line (SHG44), human glioblastoma cell lines (U251 and BT325),
and normal human astrocytes (NHA) as a control. Error bars indicate the
standard deviation of triplicate experiments
Fig. 2 Expression of ADAR2 mRNA in human glioblastomas and anal-
ysis of ADAR2 mRNA alternatively splicing variants (ASV). a Expres-
sion of ADAR2 mRNA in human glioblastomas. Real-time PCR was
performed to quantify the mRNA expression levels of ADAR2 in normal
tissues and in different grades and types of brain tumor. LGA, low-grade
astrocytoma; AA, anaplastic astrocytoma; GBM, glioblastoma
multiforme; OG, oligodendroglioma. Quantitative real-time PCR showed
that the expression of ADAR2 mRNA was not significantly different
among the tumor tissues. b Analysis of ADAR2 ASVs in glioma-derived
cell lines and glioblastomas by RT-PCR. The migration position of the
PCR reaction products corresponding to the transcripts with and without
the 47-nucleotide insert are indicated. c Analysis of ADAR2 ASVs in
glioma tissues. The ADAR2 ASV was detected in 1/10 LGAs, 1/6 OGs,
1/8 AAs, and 3/12 GBMs, corresponding to rate of self-editing-induced
ASVs of 10 %, 16.7 %, 12.5 %, and 25 %, respectively
1138 Acta Neurochir (2014) 156:1135–1142
nine ADAR2 ASV – patients, the tumor had invaded one lobe
in four patients, two lobes in four patients, and three lobes in
one patient. Therefore, the tumors in the ADAR2 ASV+pa-
tients were more aggressive than those in the ADAR2 ASV –
patients (p<0.01; Fig. 3a).
Overall survival in patients with GBM
The median survival time was 4.53 months for the three
ADAR2 ASV+patients compared with 9.98 months for the
ADAR2 ASV – patients. The difference in median survival
time between the two groups of patients was statistically
significant (p<0.0001; Fig. 3b).
Discussion
RNA editing is a common phenomenon in eukaryotic cells
that leads to post-transcriptional base changes in mRNA. In
mammals, a growing number of genes have been identified
that undergo a type of RNA editing characterized by site-
selective A-to-I modification [2, 3, 8]. The best-studied A-
to-I editing substrates are the brain-specific transcripts coding
the GluR. For GluR-B, the Q/R site controls the Ca2+ perme-
ability of the ion channel [16, 34]. ADAR2 is the main
enzyme responsible for recoding editing in the brain. It is
predominantly expressed in neurons, and is weakly expressed
in gliocytes [17]. Mammalian RNA editing catalyzed by
ADAR1 and ADAR2 plays pivotal roles in the brain by
controlling functional modifications of neurotransmitter re-
ceptors and ion channels [31]. The ADAR proteins and
RNA editing targets have been studied in many human dis-
eases associated with RNA editing, including various cancers
[6, 7, 11, 12, 26, 28].
Gliomas are the most common malignant tumors in the
central nervous system, and are almost always fatal. The
molecular basis for malignant progression in gliomas involves
several collaborative processes. Thus far, several studies have
shown that a general state of underediting exists in gliomas in
some RNA editing sites, including the Q/R site, the 5HT2C
serotonin receptor site, and the Glu/Arg site. For regulated
normal cells, these findings suggest a key role of ADAR2
editing activity in controlling the growth of gliomas [5, 22, 26,
32] because this enzyme seems to prevent cell proliferation by
the Akt pathway [16, 34] and/or modulates the cell cycle [10].
It was also reported that the Q/R site of GluR-B in gliomas is
underedited compared with that in normal tissue.
Underediting at this position might be due to decreased
ADAR2 expression or downregulation of ADAR2 enzymatic
activity.
The recent findings regarding ADAR2 mRNA expression
in gliomas were somewhat inconsistent [5, 22, 26]. The first
report, by Maas et al., showed that the ADAR2 mRNA ex-
pression was not significantly altered in one OG and seven
GBM samples, although the Q/R site of GluR-B was
underedited compared with that in control tissues [22]. Paz
et al. observed a prominent reduction in ADAR2mRNA levels
in four types of brain tumors (GBM, LGA, AA, and OG) in an
analysis of 18 brain tumors; however, their control was normal
brain tissue containing neurons, which show high ADAR2
expression [26]. Cenci et al. analyzed 14 astrocytoma tissue
samples from 10 children, and found no significant differ-
ences in ADAR2 mRNA levels between tumor tissue and
normal white matter [5].
In our study, we examined the expression of ADAR2
mRNA in human glioblastoma cell lines and in NHA,
and found no differences in its expression among these
cell types. We also determined the expression of ADAR2
mRNA in various gliomas of different grades, and
found that it was not significantly different between
gliomas and normal white matter. Based on the results
of previous studies and our study, we consider that the
expression of ADAR2 mRNA is not significantly altered
in gliomas. Thus, we speculate that underediting at the
Q/R site in gliomas is not simply due to decreased
ADAR2 expression.
The human ADAR2 gene comprises 14 exons [23, 29], and
several ASVs have been identified [1, 18, 20, 23, 27, 29]. For
example, one involving self-editing of ADAR2 pre-mRNA
creates a 3′-prime splice site within intron 1 leading to the
insertion of a 47-nucleotide sequence into the intronic se-
quence. Another ASV includes an exon located 18 kb up-
stream of the previously annotated first coding exon, and
extends the open reading frame of ADAR2 by 49 amino acids
[20]. In mammals, alternative splicing occurs within the cat-
alytic domain, the RNA-binding domain, and at the carboxy
terminus. Of these ASVs, some have no effect on editing
activity whereas others decrease the editing activity of
ADAR2. Therefore, the characterization of ADAR2 transcrip-
tion and alternative splicing is essential to understand the
regulation of RNA editing.
Table 1 Correlation between ADAR2 ASV expression and the edema/
tumor volume ratio (EI)
ADAR2 ASV (+) ADAR2 ASV (-) P value
(n=3) (n=9)
EI = 0.0005*
− 0 (0 %) 0 (0 %)
+ 0 (0 %) 7 (78 %)
+ + 0 (0 %) 2 (22 %)
+ + + 3 (100 %) 0 (0 %)
A full description of the EI is described in “Materials and methods”. EI
was graded as negative (–), weak (+), moderate (+ +), or strong (+ + +).
*Statistically significant by the Mann–Whitney U test
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The regulation of RNA editing activity in vivo remains
unknown: the amount of total ADAR2 mRNA is one factor
regulating RNA editing, but the level of total ADAR2 does
not necessarily represent the editing activity, and alternative
splicing may be another factor affecting RNA editing. Alter-
native splicing events have been demonstrated to affect the
catalytic activity of ADAR2. Rueter et al. [27] demonstrated
experimentally that the addition of 47 nucleotides to the 5’ end
of exon2 occurs due to RNA editing within intron 1 and
decreases ADAR2 activity in vivo because of the inefficient
initiation of translation from Met25. The results of Rueter
et al. are cited by several subsequent studies [18, 20]. In the
present study, we identified an ASV containing a 47-
nucleotide insertion by RT-PCR and sequencing. This ASV
Fig. 3 Magnetic resonance imaging (MRI) of glioblastomas and overall
survival analysis of patients with GBM. a MRI of glioblastomas. A
Patient with ADAR2 ASV– GBM. The lesion has invaded the temporal
and frontal lobes. B–D Patients with ADAR2 ASV+GBM. B the lesion
has invaded the temporal and frontal lobes. C The lesion has invaded the
temporal, parietal, and occipital lobes. D The lesion has invaded the
temporal, frontal, and parietal lobes. A1 axial T1-weighted image; A2,
D2 sagittal T1-weighted images; A3 coronal contrast-enhanced T1-
weighted image; B1, C1, D1 axial T2-weighted images; B2, C2 sagittal
contrast-enhanced T1-weighted image; B3, C3, D3 coronal contrast-
enhanced T1-weighted images. b Overall survival analysis of patients
with GBM. The median survival time was significantly shorter in ADAR2
ASV+patients compared with ADAR2 ASV – patients (log-rank test,
p<0.0001)
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is identical to that identified by Rueter et al., which has lower
RNA editing activity. We also detected that the expression rate
of ASV is higher in glioma than in normal white matter. On
this basis, we speculate that the expression of a less-active
ASVof ADAR2 may correlate with downregulation of A-to-I
editing in gliomas.
In our study, we found an ADAR2 ASV in two glioma-
derived cell lines, U251 and BT325, and in human glioma
tissues. The ASV was detected in 10 %, 16.7 %, 12.5 %, and
25 % of LGA, OG, AA, and GBM tissues, respectively. The
mRNA sequence of the ADAR2 ASV was identical to that
originally reported by Rueter et al. [27] and by many other
authors since then. The splicing variant is generated via a
proximal 3′ acceptor site, at which 47 nucleotides are added
to theADAR2 coding region, changing the reading frame of the
mature ADAR2 transcript. Insertion of a 47-nucleotide cassette
into the coding region shifts the translation start to an inefficient
downstream methionine. In vitro and tissue culture model
systems have indicated that the ASV downregulates the cata-
lytic activity of the human ADAR2 protein isoforms without
affecting the substrate. This finding is consistent with the as-
sumption that downregulation of A-to-I editing in gliomas may
be due to the expression of a less-active ASVof ADAR2.
We found that the positive rate of the self-editing-induced
ASV increased significantly with increasing malignancy of
the gliomas, being greatest in GBMs, the most malignant type
of glioma. To determine whether ADAR2ASVexpression was
correlated with the malignant features of gliomas, we divided
the patients with GBM into two groups according to expres-
sion of the ASV, and compared PTBE, invasiveness, and
median survival time between the two groups. These analyses
revealed that ADAR2 ASV+patients had more severe PTBE,
tumor invasion into more brain lobes, and had a shorter
median survival time compared with ADAR2 ASV – patients.
Conclusions
Our data indicate that (1) ADAR2 mRNA levels were not
altered in glioma-derived cell lines or in glioma tissues; (2)
self-editing of ADAR2 pre-mRNA generates an ADAR2
ASV in glioma-derived cell lines and glioma tissues; and (3)
expression of ADAR2 ASV may be correlated to the malig-
nancy of gliomas. Identification of the mechanistic character-
ization of ADAR2 ASV may be helpful in the future devel-
opment of individualized molecular-targeted therapy for
glioma.
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